Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2020 / N 2

Инфекционный фенотип хронической обструктивной болезни легких: особенности ведения пациентов
А.Г. Романовских, А.И. Синопальников, Ю.Г. Белоцерковская, И.П. Смирнов

References

1. Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clinics in Chest Medicine 2014 Mar;35(1):7-16.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006 Nov;3(11):e442.
3. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct;57(10):847-52.
4. Celli BR, Barnes PJ. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. The European Respiratory Journal 2007 Aug;29(6):1224-38.
5. Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J, Howard P, Gorzelak K, Lahdensuo A, Strom K, Tobiasz M, Weitzenblum E. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Archives for Chest Disease 1997 Feb;52(1):43-7.
6. Fletcher C, Peto R. The natural history of chronic airflow obstruction. British Medical Journal 1977 Jun;1(6077):1645-8.
7. Leung JM, Tiew PY, MacAogáin M, Budden KF, Yong VFL, Thomas SS, Pethe K, Hansbro PM, Chotirmall SH. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology 2017 May;22(4):634-50.
8. Dickson RP, Huffnagle GB. The lung microbiome: new principles for respiratory bacteriology in health and disease. PLoS Pathogens 2015 Jul;11(7):e1004923.
9. Monsó E. Microbiome in chronic obstructive pulmonary disease. Annals of Translational Medicine 2017 Jun;5(12):251.
10. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Update 2020). Available from: http://www.goldcopd.org/ Accessed 2020 Oct 05.
11. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respiratory Medicine 2013 Jan;107(1):10-22.
12. Garcha DS, Thurston SJ, Patel ARC, Mackay AJ, Goldring JJP, Donaldson GC, McHugh TD, Wedzicha JA. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012 Dec;67(12):1075-80.
13. Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P. Lung microbiology and exacerbations in COPD. International Journal of Chronic and Obstructive Pulmonary Disease 2012;7:555-69.
14. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2003 Apr;167(8):1090-5.
15. Marin A, Monsó E, Garcia-Nuñez M, Sauleda J, Noguera A, Pons J, Agustí A, Morera J. Variability and effects of bronchial colonisation in patients with moderate COPD. The European Respiratory Journal 2010 Feb;35(2):295-302.
16. Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? The International Journal of Chronic and Obstructive Pulmonary Disease 2017 May;12:1401-11.
17. Aliberti S, Sotgiu G, Lapi F, Gramegna A, Cricelli C, Blasi F. Prevalence and incidence of bronchiectasis in Italy. BMC Pulmonary Medicine 2020 Jan;20(1):15.
18. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2008 Apr;177(8):853-60.
19. Boutou AK, Raste Y, Reid J, Alshafi K, Polkey MI, Hopkinson NS. Does a single Pseudomonas aeruginosa isolation predict COPD mortality? The European Respiratory Journal 2014 Sep;44(3):794-7.
20. Rodrigo-Troyano A, Suarez-Cuartin G, Peiró M, Barril S, Castillo D, Sanchez-Reus F, Plaza V, Restrepo MI, Chalmers JD, Sibila O. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology (Carlton, Vic.) 2016 Oct;21(7):1235-42.
21. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, Bell SC, Thomson RM, Miles JJ. The rise of non-tuberculosis mycobacterial lung disease. Frontiers in Immunology 2020 Mar;11:303.
22. Макарова М.В., Гунтупова Л.Д. Нетуберкулезные микобактерии. БИОпрепараты. Профилактика, диагностика, лечение 2020;20(2):97-102.
23. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled cortico­steroids and risk of non-tuberculous mycobacteriosis. Thorax 2013 Mar;68(3):256-62.
24. Brode SK, Campitelli MA, Kwong JC, Lu H, Marchand-Austin A, Gershon AS, Jamieson FB, Marras TK. The risk of mycobacterial infections associated with inhaled corticosteroid use. The European Respiratory Journal 2017 Sep;50(3):1700037.
25. Huang CT, Tsai YJ, Wu HD, Wang JY, Yu SJ, Lee LN, Yang PC. Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. The International Journal of Tuberculosis and Lung Disease 2012 Apr;16(4):539-45.
26. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EFM, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. The New England Journal of Medicine 2010 Sep;363(12):1128-38.
27. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, Lindblad K, Patel H, Rugman P, Dodson P, Jenkins M, Saunders M, Newbold P, Green RH, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, Brightling CE. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. American Journal of Respiratory and Critical Care Medicine 2011 Sep;184(6):662-71.
28. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. The New England Journal of Medicine 2008 Nov;359(22):2355-65.
29. Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacterial and exacerbations of chronic obstructive pulmonary disease. The New England Journal of Medicine 2002;347:465-71.
30. Provost KA, Frederick CA, Sethi S. Triggers of pulmonary exacerbation. Bacterial infection. In: Acute exacerbations of pulmonary disease. ERS monograph. Burgel PR, Contoli M, López-Campos LL, editors. Sheffield, UK: ERS; 2017: 97-113.
31. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 1987 Feb;106(2):196-204.
32. Soler N, Agustí C, Angrill J, De la Bellacasa JP, Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007 Jan;62(1):29-35.
33. Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas-Jones E, Wootton M, Hood K, Phillips R, Melbye H, Llor C, Cals JWL, Naik G, Kirby N, Gal M, Riga E, Francis NA. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. The New England Journal of Medicine 2019 Jul;381(2):111-20.
34. Miravitlles M, Moragas A, Hernández S, Bayona C, Llir C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest 2013 Nov;144(5):1571-7.
35. Российское респираторное общество. Клинические рекомендации по хронической обструктивной болезни легких. Доступно по: http://cr.rosminzdrav.ru/#!/recomend/908 Ссылка активна на 05.10.2020.
36. Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? International Journal of Chronic Obstructive Pulmonary Disease 2017;12:1401-11.
37. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respiratory Medicine 2012 Aug;106(8):1124-33.
38. Maselli DJ, Restrepo MI. Pneumonia or exacerbation of COPD? In: Controversies in COPD. ERS monograph. Anzueto A, Heijdra Y, Hurst JR, editors. Sheffield, UK: ERS; 2015: 185-96.
39. Gómez-Junyent J, Garcia-Vidal C, Viasus D, Millat-Martínez P, Simonetti A, Santos MS, Ardanuy C, Dorca J, Carratalà J. Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One 2014;9(8):e105854.
40. Ramirez JA, Cavallazzi R. Community-acquired pneumonia pathogenesis in patients with chronic obstructive pulmonary disease. University of Louisville Journal of Respiratory Infections 2019 Nov;3(2):4.
41. Williams NP, Coombs NA, Johnson M, Josephs LK, Rigge LA, Staples KJ, Thomas M, Wilkinson TM. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked healthcare records. International Journal of Chronic Obstructive Pulmonary Disease 2017 Jan;12:313-22.
42. Finney L, Berry M, Singanayagam A, Elkin SL, Johnston SL, Mallia P. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. The Lancet. Respiratory Medicine 2014 Nov;2(11):919-32.
43. Suissa S, Dell’Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD cohort study in real-world clinical practice. Chest 2020 Apr;157(4):846-55.
44. European Medicines Agency. EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease. Press release 2016 Apr 29. Available from: https://www.ema.europa.eu Accessed 2020 Oct 05.
45. Авдеев С.Н., Айсанов З.Р., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И., Mира­витлс M. Отмена ингаляционных глюкокортикостероидов у пациентов с хронической обструктивной болезнью легких. Пульмонология 2019;29(3):334-45.
46. Hurst JR. Consolidation and exacerbation of COPD. Medical Sciences (Basel, Switzerland) 2018 Jun;6(2):44.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]